42. A compound according to claim 1, wherein the compound is 2-(2-ethylbenzyl)-4,5-dihydroxyisophthalonitrile.

43. A compound according to any one of claims 1 to 42 for use as a medicament.

44. Use of a compound according to any one of claims 1 to 42 for the manufacture of a medicament for the treatment of a disease or condition where a COMT inhibiting agent is indicated to be useful, wherein the disease is Parkinson's disease.

45. A pharmaceutical composition comprising as active ingredient at least one compound according to any one of claims 1 to 42 and a pharmaceutically acceptable carrier, diluent, excipient or a mixture thereof.

46. A pharmaceutical composition according to claim 45, wherein the composition further comprises at least one other active ingredient.

47. A pharmaceutical composition according to claim 46, wherein the composition comprises levodopa and carbidopa.